Hospital drug prices are up to 7 times greater than Medicare pricing

15 February 2019 - A new study shows something many healthcare patients know all too well: hospitals are charging significant ...

Read more →

What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.

7 February 2019 - Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work ...

Read more →

Comparing PHARMAC's outcomes with those of Australia

7 February 2019 - New Zealand's Prime Minister Jacinda Ahern's claim that is unfair to compare PHARMAC's outcomes with those ...

Read more →

Jacinda Ardern: not fair to compare PHARMAC with Australia's system

5 February 2019 - Jacinda Ardern told The AM Show New Zealand's drug buying agency has "been pointed to as being ...

Read more →

The U.S. should assess the economic value of drugs rather than leave it up to other countries

17 January 2019 - One reason why prescription drugs are often priced lower overseas is that many countries perform detailed ...

Read more →

Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score

19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...

Read more →

Dozens of groups attack Trump plan to peg drug prices to what other countries pay

10 December 2018 - A controversial Trump administration plan to lower drug costs by pegging prices to what are paid ...

Read more →

International price index for medicine will harm patients

4 December 2018 - President Trump was elected on his promise to stop other nations from taking advantage of the ...

Read more →

The bizarre world of drug pricing

19 November 2018 - There is no shortage of bad ideas when it comes to the pharmaceutical market. One such ...

Read more →

PBAC shows no propensity to support Amgen's innovative method of analysis

12 November 2018 - Amgen's recent submission for blinatumomab (Blincyto) treatment of patients with B-cell precursor acute lymphoblastic leukaemia in haematological ...

Read more →

Comparison of U.S. and international prices for top Medicare Part B drugs by total expenditures

25 October 2018 - The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as ex- manufacturers prices) ...

Read more →

Outdated public funding model failing New Zealand patients

9 October 2018 - Publicly funded modern medicines are out of reach for many patients in New Zealand according to ...

Read more →

This drug is safe and effective. Wait. Compared with what?

20 August 2018 - Comparative effectiveness research may be the best way to answer questions that patients and physicians face every ...

Read more →

FDA analysis shows similar success rates for paediatric trials using clinical and surrogate outcomes

21 August 2018 - An analysis by US FDA officials published earlier this month finds that there is a similar ...

Read more →

Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?

8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...

Read more →